RANBAXY'S MOHALI SEZ FACILITY BEGINS EXPORT OF ATORVASTATIN TO THE US MARKET
Gurgaon, India April 02, 2012
Ranbaxy Laboratories Limited today announced that the company has commenced exports of Atorvastatin Calcium Oral Tablets to the US market, from its state-of-the-art Mohali SEZ manufacturing facility, located in Punjab, India.
The first consignment of Atorvastatin Tablets has been dispatched to the US market in March 2012. The supply of Atrovastatin tablets from India supplements the Company's current production from Ohm Laboratories Inc, USA.
Commenting on the development, Mr. Arun Sawhney, CEO & Managing Director, Ranbaxy said, "The resumption of supplies from India into the US market, is a significant milestone for Ranbaxy. This is a testimony to our commitment to provide quality affordable medicines to the US healthcare system. Going forward, our Mohali facility will cater to the US and other geographies, improving access to medicines, in these regions."
Ranbaxy's dosage forms facility at Mohali was approved by the US Food and Drug Administration (FDA) in October 2011. Thereafter, in the first quarter of 2012, the company received approval from the US FDA to manufacture and market Atorvastatin 10mg, 20mg, 40mg and 80mg tablets. Earlier, international regulatory authorities such as the WHO-Geneva, National Medicine and Medical Devices Agency (NMMDA)-Romania, ANVISA-Brazil, TGA-Australia, Canada Health-Canada etc. had also approved the Company's Mohali facility.
The new facility at Mohali will manufacture oral solid products for export to US, EU and other countries based on filings and after receiving the necessary approvals. It is equipped with the latest state-of-the-art technology, designed to meet global and local regulatory requirement and conforms to cGMP standards.
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.
For further information please contact:
Raghu Kochar
Director - Corporate Communications
email: [email protected]
Tel: +91-124-4135141
Mobile: 9811617256
Krishnan Ramalingam
General Manager - Corporate Communications
email: [email protected]
Tel: +91-124-4135143
Mobile: 981004254
Gaurav Chugh
Senior Manager- Corporate Communications
Email: [email protected]
Tel: +91-124-4135145
Mobile: 9810471414